A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Crenigacestat (Primary) ; Abemaciclib; Cisplatin; Gemcitabine; LY 3023414; Taladegib
- Indications Advanced breast cancer; Cholangiocarcinoma; Colon cancer; Lymphoma; Male breast cancer; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 15 Sep 2017 Planned End Date changed from 1 Aug 2018 to 1 Sep 2018.
- 15 Sep 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Apr 2018.
- 09 Dec 2016 Status changed from not yet recruiting to recruiting.